Table 1.

Patient Characteristics

	AMB Period vs. AZ Period
	AMB	AZ	Odds Ratio1	p-value
No. of Hospitalizations	259	321
No. of Patients	181	216
Mean Age2	49.6 yrs (19 – 86 yrs)3	50.3 yrs (18 – 83 yrs)		<0.0014
Gender	65% male	55% male	OR = 0.00	0.00095
Diagnoses
NHL	74 (29%)	102 (32%)	OR = 0.96	0.97
Hodgkin's Disease	11 (4%)	19 (6%)	OR = 1.38	0.85
Myeloid Neoplasms	96 (37%)	111 (35%)	OR = 0.56	0.6
Lymphocytic Leukemia	46 (18%)	40 (12%)	OR = 0.58	0.66
Multiple Myeloma	25 (10%)	39 (12%)	OR = 1.16	0.9
Other	7 (3%)	10 (3%)	OR = 6.45	0.25
Therapy
Mini-transplant	14 (8%)	15 (5%)	OR = 0.98	0.965
Allo-transplant	3 (2%)	23 (7%)	OR = 2.62	0.225
Auto-transplant	39 (22%)	42 (13%)	OR = 0.63	0.035
Chemotherapy	113 (62%)	136 (42%)	OR = 1.16	0.555
Other	11(6%)	19 (6%)	OR = 1.24	0.595
Twin-transplant	1 (0.6%)	0
Mean Length of Stay2	20.9 days (19–23 days)	19.2 days (17.5–21.1 days)		0.214
Mean Duration of therapy2	19.8 days (17.9–21.8 days)	16.5 days (15–18.1 days)		0.0094

¹Odds ratios are from random effects regression models that controlled for the number of hospitalizations. The reported odds ratios are the odds of having the individual variables in the AZ period relative to the AMB period

²Reported means are least squared means from mixed effects regression models that controlled for the number of hospitalizations

³age range is the observed age range of the patients in each period

⁴p-values are from mixed effects logistic regression models that controlled for the number of hospitalization

⁵p-values are from random effects logistic regression models that controlled for the number of hospitalization

Note: AMB = amphotericin; AZ = Azole; FLU = fluconazole; VOR = voriconazole; NHL = non-Hodgkin's lymphoma; OR = odds ratio; Allo-transplant = allogeneic stem cell transplant; auto-transplant = autologous stem cell transplant